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The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal
and myeloid cells in response to proinflammatory signals and microbial moieties. The
prototype of the pentraxin family is C reactive protein (CRP), a widely-used biomarker
in human pathologies with an inflammatory or infectious origin. Data so far describe
PTX3 as a multifunctional protein acting as a functional ancestor of antibodies and
playing a regulatory role in inflammation. Cardiovascular disease (CVD) is a leading
cause of mortality worldwide, and inflammation is crucial in promoting it. Data from
animal models indicate that PTX3 can have cardioprotective and atheroprotective roles
regulating inflammation. PTX3 has been investigated in several clinical settings as
possible biomarker of CVD. Data collected so far indicate that PTX3 plasma levels rise
rapidly in acute myocardial infarction, heart failure and cardiac arrest, reflecting the extent
of tissue damage and predicting the risk of mortality.
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INTRODUCTION
According to the World Health Organization (WHO), an estimated 17 million people globally
die of cardiovascular diseases (CVD) every year, with important implications in terms of quality
of life and social costs1 Experimental and clinical evidence points to inflammation as a major
cause of atherosclerosis, the underlying mechanism of CVD (1, 2). Accordingly, therapies targeting
inflammation show promising results, as demonstrated by the successes of statins therapy, due not
only to their effects on cholesterol, but also on the control of inflammation (3); or anti-interleukin-
1β (IL-1β) appears to lower cardiovascular event rates (4).
The inflammatory response is mediated by a set of cells and soluble proteins belonging to the
innate immune system. The humoral arm of the innate immune response includes components of
the complement cascade and soluble pattern recognition molecules (PRM), particularly collectins
(surfactant protein-A, [SP-A], and SP-D), ficolins, (ficolin-1;−2;−3) and members of the pentraxin
family (C-reactive protein [CRP], serum amyloid P component [SAP], and long pentraxin 3
[PTX3]) (5–7). Therefore, soluble PRM are a heterogeneous group of proteins acting as functional
ancestors of antibodies and key roles as regulators of inflammation playing as effectors and
modulators of the innate immune response in animals and man.
1Source: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/cardiovascular-
diseases2.
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CRP, one of the prototypic molecules of the pentraxin family,
is a systemic biomarker of inflammation widely used in the
clinic to monitor infections and inflammatory conditions (7).
Epidemiological studies have consistently associated raised CRP
serum levels with an increased risk of acute myocardial infarction
(MI), stroke, and peripheral artery disease (8). In studies to date,
CRP has emerged not only as a biomarker of CVD, but also as an
independent predictor of adverse cardiovascular events.
PTX3, identified as a cognate molecule of CRP, is a
multifunctional protein with complex regulatory roles in
inflammation and extracellular matrix organization and
remodeling (9). In men and mice PTX3 blood levels rise rapidly
and dramatically in different pathological conditions with an
inflammatory and/or infectious origin and have been investigated
in several studies (Figure 1). The main characteristic of PTX3
is that it rises faster than CRP (peak at 6–8 h for PTX3; 24–48 h
for CRP), very likely because of local vs. systemic production
of the two proteins (9). The question is “How can a member
of the humoral innate immunity be involved in cardiovascular
health and disease?” Here we review the key properties of PTX3
as prototypic member of the pentraxin superfamily in relation to
cardiovascular pathology.
The properties of PTX3 have been widely studied in humans
and mice, using genetic approaches made possible by the
high level of conservation of this molecule among species (5).
The review will specifically deal with (1) vascular disorders,
in which PTX3 has been found to play a role, but also (2)
cardiac diseases such as myocardial infarction, heart failure (HF)
and cardiac arrest (CA). While it has long been known that
atherosclerosis is an inflammatory disease (10) and consequently
innate and adaptive immune responses are expected to play a
role, the involvement of PTX3 in cardiac diseases is somewhat
less evident.
THE PENTRAXIN SUPERFAMILY: CRP
AND PTX3
The Pentraxin superfamily comprises long and short pentraxins
(9). CRP and SAP were identified as the prototypes of the short
pentraxin family; PTX3 was cloned in the late 1980’s and is
considered the prototype of the long pentraxin arm, its gene and
protein sequences being almost twice the sequences of CRP and
SAP. PTX3 is a key molecule playing complex regulatory roles
at the crossroads of innate immunity, inflammation, tissue repair
and cancer (9). A strong association has been reported between
PTX3 genetic variants, affecting circulating levels of the protein,
and susceptibility to fungal infections, suggests therapeutic use of
the protein (11–15).
The main biochemical and biological characteristics of CRP
and PTX3 have been amply described in several reviews, some of
which published very recently (7, 9). Here we will only underline
the main differences between the two proteins and some aspects
possibly helpful to define their role in CVD.
Although both CRP and PTX3 are considered acute phase
proteins, they differ in their producing cells and inducing
stimuli. The short pentraxins CRP and SAP are produced
FIGURE 1 | Number of publications/year from PubMed and Embase on PTX3
as an early indicator of acute myocardial infarction and cardiovascular
diseases in humans. SEARCH QUERY: (ptx3 OR “pentraxin 3”/exp/ descriptor)
AND “cardiovascular disease”/exp/descriptor AND 2000–2018*. Same search
strategy was applied for PTX3 AND Atherosclerosis, Acute Myocardial
Infarction (AMI), Heart Failure (HF) and cardiac arrest (CA). * 2018 included only
10 months.
primarily in the liver in response to IL-6, reflecting a systemic
response, while PTX3 is produced locally by a wide range of
stromal and myeloid cells, including monocytes, endothelial cells
(EC), and fibroblasts, but not hepatocytes (Figure 2). Primary
pro-inflammatory signals, interleukin- (IL-) 1β (IL-1β) and
TNFα, or bacterial moieties engaging Toll-like receptors (TLR),
such as bacterial lipopolysaccharides (LPS), flagellin and outer
membrane proteins, are major inducers of PTX3, while IL-6 is
ineffective. Polymorphonuclear leucocytes (PMN) have a store
of mature PTX3 produced during the differentiation from bone
marrow precursors and accumulated in their granules, ready
to be released in response to microbial recognition or tissue
damage (16).
Vascular EC are a major source of PTX3 in response to
inflammatory signals. Anti-inflammatory and atheroprotective
signals, such as high density lipoproteins (HDL) and IL-10 induce
PTX3 expression. This suggests a potential regulatory role of
PTX3 in the innate and adaptive immune responses as well as
being an anti-atherogenic molecule (17–19).
The NF-κB pathway is involved in the cascade of molecular
events leading to PTX3 expression, as initially demonstrated in
a model of acute myocardial ischemia (AMI) and reperfusion in
mice (20), and subsequently confirmed by other studies (21, 22).
In the model of myocardial infarction in mice, induction of
ischemia resulted in upregulation of PTX3 production, an effect
almost completely absent in il-1r1- ormyd88-deficient mice.
Recent data have indicated a role of PTX3 in tissue remodeling
and repair. In different models of tissue damage, PTX3 was
localized in the pericellular provisional fibrin matrix, where
it promoted migration and invasive phenotype of remodeling
cells (23). Excessive fibrin accumulation was observed in skin,
liver and lung injury models in ptx3-deficient mice, while
in a murine model of arterial thrombosis PTX3 released by
EC inhibited platelet aggregation, dampening thrombogenesis
(23, 24). In addition, PTX3 is involved in edema resolution
and scar formation in a model of brain ischemic injury in
mice (25). Finally, we recently reported a non-redundant role
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FIGURE 2 | Cellular sources and main functions of the long pentraxin PTX3. The protein is induced by primary proinflammatory stimuli, TLR engagement, microbe
recognition and ischemia by myeloid and stromal cells. PTX3 is a multifunctional protein playing a role in the orchestration of tissue repair through the regulation of
fibrin deposition, and it regulates inflammation, modulating complement activity and limiting neutrophils infiltration in inflamed tissues. Finally, PTX3 is a molecule of the
innate immunity and exerts protective roles against selected pathogens acting as and opsonin. The functional role of PTX3 in the main discussed pathology is
highlighted by asterisks. However, for some of them, PTX3 has been explored only as a biomarker and there is little evidence of its functional involvement.
of PTX3 in physiological skeletal remodeling and in proper
matrix mineralization during bone fracture repair (26). These
observations illustrated how PTX3 can play essential roles in
tissue remodeling and repair.
The data summarized here indicate the complex regulation
of PTX3 production from different cell types in response to
different stimuli, and very likely reflect the different roles of this
multifunctional protein in the innate immune response and as a
constituent of the extracellular matrix. In addition, the induction
of PTX3 by anti-inflammatory and atheroprotective signals such
as HDL and IL-10 may reflect a possible protective function of
PTX3 on EC and vascular integrity.
PTX3 is also expressed during sterile inflammation. For
instance, in the model of experimental myocardial infarction
(MI) mentioned, ptx3-deficient mice had greater myocardial
lesions, more leukocyte infiltration, more cell death and
higher complement C3 deposition in the infarcted area
(20). This suggests that PTX3 might have a non-redundant
cardioprotective role in mice, acting on the inflammation and
tissue damage associated with reperfusion possibly by affecting
the classical and the alternative pathways of complement
activation (20). In addition, PTX3 can regulate leukocyte
extravasation through an interaction with P-selectin (27),
reducing neutrophil recruitment in inflamed sites. PTX3 can also
interact with platelets via P-selectin exposed on their surface,
and dampens the proinflammatory and prothrombotic effects
of activated platelets, further contributing to a cardioprotective
role (28).
In contrast, in a mouse model of transverse aortic
constriction (TAC), PTX3 modulated the hypertrophic
response and ventricular dysfunction following an increased
afterload. Specifically, echocardiography indicated that PTX3
overexpression promoted tissue remodeling, left ventricular
dysfunction, and increased myocardial fibrosis, while these
responses were suppressed in ptx3-deficient mice (29).
PTX3 IN CVD
The findings summarized above underline the dual role of PTX3
in sterile and non-sterile inflammation. Here we will examine the
role of PTX3 in four cardiovascular disorders:
1. Atherosclerosis,
2. Acute MI (AMI)
3. Heart failure (HF)
4. Cardiac arrest (CA).
We briefly discuss the evidences of the possible roles played by
PTX3 and its potential as a circulating biomarker of diagnosis
and/or prognosis in each disease.
Atherosclerosis
PTX3 is produced by different cell types potentially involved
in atherosclerosis, in particular EC, smooth muscle cells and
macrophages (Figure 2). Staining of advanced atherosclerotic
lesions in humans showed strong expression of PTX3,
mainly by macrophages and EC, but also by smooth
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muscle cells (30). Different pro-inflammatory molecules
are produced in an atherosclerotic lesion, particularly
cytokines such as TNFα and IL-1, and oxidized low-
density lipoproteins (oxLDL) These soluble factors may
well be responsible for the production of PTX3 by target
cells (31).
Investigations were made in PTX3/apolipoprotein E double
knockout mice (ptx3/apoE-/-) The lack of PTX3 in animals
with a genetic background making them susceptible to
atherosclerosis resulted in larger areas of atherosclerotic
lesions, greater accumulation of macrophages, higher expression
of adhesion molecules, cytokines and chemokines in the
vascular wall (19). Vascular inflammation was more marked,
suggesting that PTX3 could exert an atheroprotective effect
in mice.
Smooth muscle cells are important players in atherosclerosis
and are activated after arterial injury. The soluble mediators
produced by injured arteries include fibroblast growth factor
2 (FGF2), one of the well-characterized ligands recognized
by PTX3 (32, 33). FGF2 plays important roles in vivo by
promoting angiogenesis and revascularization during wound
healing, inflammation, atherosclerosis, and tumor growth. PTX3
has been reported to act as a competitor of FGF2, blocking its
interaction to its receptor and thus influencing neo-angiogenesis.
In addition, it has been recently reported that PTX3 interaction
with FGF2 might contribute to the maintenance of bone mass
in homeostatic and pathological conditions, affecting the cross-
talk between inflammatory cells and endothelium (26, 34). The
specific interaction between PTX3 and FGF2 also results in
the inhibition of FGF-dependent proliferation in vitro (35). In
addition, FGF2 exerts a potent inhibitory effect on the activation
of smooth muscle cells, suggesting that PTX3 might affect the
activation of SMC after arterial injury (35).
In summary, there are various evidences that PTX3 may play
a role in atherosclerosis:
1. PTX3 is expressed more in leukocytes and in adipose tissue
from patients with high levels of low-density lipoprotein
(LDL) compared to those with low levels (36).
2. PTX3 expression in visceral fat of obese individuals is
determined by both LDL/ high density lipoprotein (HDL)
ratio and fibrinogen (37).
3. Treatment of EC with lysophosphatidic acid led to a marked
upregulation of PTX3 both in terms of mRNA and protein
level (38).
4. Immunohistochemistry (ICH) on human atherosclerotic
lesions showed that macrophages and PMN cells infiltrating
the atherosclerotic plaques were positive for PTX3 (30, 39).
5. PTX3 expression in human EC was upregulated by
HDL, whereas there were no effects on CRP and SAP
expression (19).
6. In apolipoprotein E-deficient mice, the inflammatory reaction
of the vascular wall and macrophage accumulation in the
plaque were markedly increased by the lack of PTX3 (19, 31).
7. PTX3 plays a protective role in arterial thrombosis by
dampening the pro-thrombotic effects of fibrinogen and
collagen (23, 24)
Acute Myocardial Infarction (AMI)
One of the first in vivo findings on PTX3 was its high
expression in murine hearts after injection of LPS (40). Specific
immunostaining for PTX3 was also observed in heart tissues
of patients who died of MI (41). In early ischemic lesions
PTX3 expression was high primarily in PMN cells, while in
more advanced lesions PTX3 positivty of granulocyte was lost
and was mainly acquired by macrophages, EC and sometimes
myocardiocytes (Figure 2).
The high conservation of PTX3 in evolution allows us to
translate to humans the observations in mice, whereas CRP and
SAP expression is regulated differently in mice and man. Based
on this consideration, a model of experimental MI based on
coronary artery ligation and reperfusion was applied to ptx3-
deficient mice (20). In this model, PTX3 mRNA expression was
upregulated in the left ventricle (LV) of wild- type animals and
circulating levels of the protein were increased, with a peak
at 24 h. IHC and confocal microscopy confirmed that major
sources of PTX3 in the infarcted heart are first granulocytes
and EC (24 h after reperfusion), followed by macrophages, that
became positive 3 days after reperfusion. Similarly, PTX3 is
released from neutrophils in the early phases of AMI in humans
(28), contributing to the rapid increases in different studies
(see below). Infarct sizes were measured in wild type and ptx3-
deficient mice, and the larger damaged area was in the absence
of the protein (20). Thus, the presence of PTX3 observed by
IHC in tissue samples from mice after ischemic injury and
confirmed in the heart of patients who died from MI, supports
a pathophysiologic role of the protein in myocardial damage
and repair.
Regulation of complement activation by PTX3 has been
considered a possible mechanism involved in tissue damage
after ischemia and reperfusion. The interaction of PTX3 with
Factor H (FH), the most important regulator of the alternative
complement pathway, was important to limit FH deposition on
PTX3-coated surfaces and to protect against oxidative stress-
induced complement and inflammasome activation (42, 43). In
addition, deposition of FH and higher complement activation
was lower in tumors growing in ptx3-deficient mice (44).
These observations strongly sustain the hypothesis that the
PTX3-FH interaction may constitute a mechanism to prevent
excessive complement activation. In the infarcted heart, C3
deposition was higher in ptx3-deficient mice and complement
depletion canceled the difference between wild- type and ptx3−/−
mice (20).
Whether PTX3 plays a role in the progression of post-
infarction left ventricular dysfunction and failure has
been the subject of research in the mouse after coronary
ligation. The results have been mostly inconclusive but
nonetheless it can be concluded with some confidence that
the role of PTX3 in left ventricular remodeling after MI is
practically irrelevant.
The production of PTX3 by vascular cells in response to
inflammatory signals and ox-LDL (17, 31) and its occurrence
in atherosclerotic lesions (30, 45), prompted investigations of
PTX3 levels in AMI (46–52). A high- sensitive (lower detection
limit 0.1 ng/mL), specific (no cross-reaction with human CRP
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FIGURE 3 | Representative concentrations of PTX3 in healthy volunteers and
in different cardiovascular diseases. Data were extrapolated from four different
publications evaluating PTX3 levels in plasma samples by sandwich ELISA.
Specifically, PTX3 levels in healthy volunteers and in acute myocardial infarction
(AMI) patients are from Peri et al. (53) in heart failure (HF) patients are from
Latini et al. (56) in cardiac arrest (CA) patients are from Ristagno et al. (57) and
in severe sepsis/septic shock patients are from Caironi et al. (58). PTX3 levels
are presented as median (interquartile range). Numbers over bars represents
the median value of plasma concentration of PTX3 expressed in ng/mL.
and SAP) ELISA based on original reagents was developed and
used tomeasure circulating levels of PTX3 in patients and healthy
volunteers. Plasma PTX3 in healthy subjects was ≤ 2 ng/mL,
with higher levels in females than males and levels increased
with aging (53–55). Patients with AMI showed an early peak
of PTX3 plasma levels observed within 6–8 h from symptom
onset (Figure 3), and baseline levels were reached within 3 days
(53, 59). In a cohort of 748 patients with MI and ST elevation
enrolled in the Lipid Assessment Trial Italian Network (LATIN),
PTX3, CRP, pro b-type natriuretic peptide (NT-proBNP) and
troponin-T were measured within the first day from the onset of
symptoms. Among all these markers, PTX3 levels >10.73 ng/mL
within the first day after MI were the only independent predictor
of three-month mortality (56). High PTX3 also predicted long-
term mortality in several subsequent prospective observational
studies (50–52).
Besides being a biomarker of MI reflecting the degree of
tissue damage, PTX3 was proposed as a prognostic tool in two
large studies aiming to identify predictive factors of CVD: the
Cardiovascular Health Study (1,583 patients analyzed) and the
Multi-Ethnic Study of Atherosclerosis (2,880 patients). These
two studies illustrated a significant relation between PTX3 levels
and cardiovascular mortality and all-cause death (60, 61). In
addition, it was recently shown that higher PTX3 levels predicted
occurrence ofMI in a cohort of young ormiddle-aged individuals
followed for a first-time MI (62).
It is not clear yet whether the impressive relation with fatal
outcome seen in most of the clinical studies actually reflects a role
of PTX3 on the pathogenesis of damage, for instance through
amplification of the complement and coagulation cascades (63,
64), or amarked protective response to severe cardiac injury. This
question has not yet been addressed, nor has that more related
to the potential role of PTX3 as an early prognostic biomarker
in MI.
Heart Failure (HF)
The role of inflammation in the progression and outcome of heart
failure (HF) is still under discussion. High levels of circulating
inflammatory molecules, in particular cytokines and CRP, are
related to more severe HF and worse outcomes. However,
whether inflammation is a cause or just a consequence of
the disease is a matter of controversy. In addition, none of
the inflammatory cytokines measurable in the plasma of HF
patients can be used singly as a basis for prognosis (65), or
even when a multi-marker approach including a range of soluble
inflammatory mediators and PTX3, was considered (66).
The prognostic role of PTX3 in chronic HF with reduced
(67, 68) or preserved (69, 70) ejection fraction has been reported
in several small studies (with ≤ 200 patients each). PTX3
levels correlated weakly with those of brain natriuretic peptide
(BNP), and ROC analysis suggested that PTX3 was superior to
BNP in the prediction of adverse outcomes (68). Other studies
(with 37–164 patients) showed that the best risk prediction
was achieved by combining three biomarkers: BNP, H-FABP
and PTX3 (67, 71). Importantly, high levels of PTX3 correlated
significantly with the presence of HF among patients with normal
LVEF and LV diastolic dysfunction (69). PTX3 was assayed at
randomization and after 3 months in 1,233 patients from the
GISSI-Heart Failure trial (GISSI-HF) and 1,457 patients from the
Controlled Rosuvastatin Multinational Trial in HF (CORONA)
(72). PTX3 was independently and significantly related to the
severity of HF. In addition, PTX3 levels were higher in older
individuals with ventricular dysfunction, worse symptoms and
co-morbidity, i.e., atrial fibrillation or diabetes. Most important,
baseline concentrations of PTX3 and three-month changes were
significantly related to fatal outcome (72). Similarly, a long-
term prospective study on patients with HF and normal ejection
fraction indicated that high baseline circulating levels of PTX3
were predictive of all-cause mortality, cardiovascular mortality or
hospitalization for worsening HF (70).
The effects of rosuvastatin in the GISSI-HF and CORONA
studies deserve a comment. Rosuvastatin (10 mg/day for 3
months) consistently reduced circulating levels of high-sensitive
CRP (hsCRP) in both the CORONA trial and GISSI-HF, in line
with its anti-inflammatory properties. In contrast, the CORONA
trial found an unexpected, opposite effect on PTX3, which
increased significantly more in rosuvastatin- treated patients
than with placebo (72). This controversial observation might
be explained by the hypothesis that statins alter the innate
immunity behavior of stimulated phagocytic cells and enhance
the production of macrophage and neutrophil extracellular traps
that contain antimicrobial proteins and PTX3 (16, 73). This
hypothesis, based on clinical and epidemiological observations
of lower susceptibility to severe bacterial infection in patients
receiving statin therapy, remains highly speculative but calls for
further investigation. According to these findings CRP and PTX3
seem to exert different but, to a certain extent, overlapping roles
in systemic and local inflammation.
Cardiac Arrest (CA)
Despite the return of spontaneous circulation (ROSC), mortality
after resuscitation from cardiac arrest remains extremely high
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(74). The well-known “post-cardiac arrest syndrome” (PCAS)
is characterized by myocardial dysfunction with circulatory
shock, systemic inflammation, and evolving brain injury (75).
Thus, clear similarities between sepsis, septic shock and
PCAS have been acknowledged (76). Indeed, upon reperfusion
after ROSC, a systemic inflammatory response occurs and
ultimately contributes to worsening of circulatory shock and
neurological damage.
Recently PTX3 has been investigated in comparison with
the classic hsCRP for the prediction of early multiple organ
dysfunction syndrome (MODS), early death, and long-term
outcome after CA. More specifically, PTX3 and hsCRP were
assayed at admission to intensive care unit (ICU) and 2 days later
in 278 out-of-hospital CA patients enrolled in the prospective
observational cohort study FINNRESUSCI, conducted in 21
hospitals in Finland (57). In this population, at ICU admission
hsCRP was normal, i.e., 2.8 [1.2–9.8] mg/L, while PTX3 already
showed large increases, i.e., 19.1 [9.2–41.8] ng/mL and levels
were higher in older patients and in patients resuscitated after
longer CA. Higher plasma levels of PTX3 were significantly
associated with MODS [AUCs 0.78 (p < 0.0001)], and values
above 24 ng/mL showed 0.8 sensitivity and 0.7 specificity for
predicting MODS. HsCRP, instead, presented a lower accuracy
(AUC of 0.6, p = 0.033) compared to PTX3 (p < 0.003) in
predicting MODS occurrence. PTX3 plasma levels were already
significantly higher at ICU admission in patients who developed
MODS and died in the ICU compared to those who did
not experience MODS and survived to ICU discharge. HsCRP
levels discriminated for MODS and ICU death only 48 h after
admission (57).
After ROSC, the levels of soluble intercellular adhesion
molecule-1, soluble vascular-cell adhesion molecule-1, and P-
and E-selectins showed early increases indicating leucocyte and
endothelial activation. This condition is ultimately associated
with a rapid PTX3 increase, as illustrated by the 10-fold higher
plasma levels already observed at ICU admission in the cohort
study. Thus, early PTX3 levels, i.e., at ICU admission after ROSC,
are independent predictors of MODS and early death, while CRP
is not. Moreover, since PTX3 levels continue to rise during ICU
recovery, the post-CA pro-inflammatory response is prolonged
and could be therefore a potential target for intervention (57).
PTX3 as Circulating Biomarker in CVD
Preclinical data in the mouse and the homology with CRP, a
molecule used to monitor inflammatory diseases and infection
in clinical practice, prompted investigation of PTX3 as possible
marker of human pathology. As seen above, PTX3 has been
investigated as a possible circulating biomarker in MI, HF and
CA, but the numbers of pathological conditions potentially
involving PTX3 as biomarker are larger. The rapid rises in PTX3
plasma levels are compatible with an acute phase response. PTX3
blood levels can reach 800 ng/ml in patients with endotoxin
shock, sepsis and infections of viral, bacterial or fungal origin
(58, 77–83). In general, PTX3 circulating levels were significantly
correlated with the severity of disease and mortality, and served
to monitor the response to therapy. In addition, PTX3 levels
rarely correlate with CRP, indicating that the two proteins
might have different roles. This lack of correlation was useful
to distinguish the presence and absence of shock in a small
cohort of patients with meningococcal disease (80). In addition,
myeloproliferative disorder patients with major thrombosis had
higher levels of hsCRP and lower levels of PTX3, thus confirming
that the two molecules modulate cardiovascular risk factors in
opposite ways (84).
The diagnostic and prognostic value of circulating PTX3 was
tested in recent studies on patients with severe sepsis and septic
shock. The Albumin Italian Outcome Sepsis (ALBIOS) trial
reported that high levels of PTX3 measured in a cohort of 958
patients on day 1 after admission to the ICU were able to predict
new organ failures, while a smaller drop in circulating PTX3 over
time predicted an increased risk of death (58). Similar increases
in plasmatic levels of PTX3 and associations with mortality
in patients with sepsis or septic shock were reported in other
studies (85–88).
PTX3 plasma levels were significantly elevated in patients with
arterial inflammation who underwent percutaneous coronary
intervention (PCI) (54, 89, 90). Systemic PTX3 levels before
PCI were associated with larger plaque area and volume, a
higher risk of plaque rupture at the culprit site and impaired
post-PCI myocardial perfusion (49). A study on 594 patients
with stable coronary artery disease (CAD) reported that PTX3
plasma levels were higher 24 h after PCI than before (91). During
the follow-up for major adverse cardiovascular events, patients
with higher post-PCI levels of PTX3 had a higher incidence of
events. Similarly, in patients with angina who underwent PCI,
PTX3 levels resulted to be an independent risk factor associated
to troponin increase after PCI (92). These data suggest that
PTX3 could provide a reliable marker for risk stratification in
patients undergoing PCI. Patients with unstable angina pectoris
have higher PTX3 levels than healthy controls, suggesting that
this long pentraxin might be a candidate marker to unstable
angina (54).
PTX3 has also been proposed as a novel marker for stent-
induced inflammation in patients with CAD after PCI (93).
PTX3 was increased in peripheral blood and in the coronary
sinus of 20 patients undergoing coronary stenting. Expression of
CD11b/CD18 on neutrophils correlated with PTX3 levels. The
relative PTX3 increase observed at 24 h was the most powerful
predictor of late lumen loss. In the same setting, CRP could
not discriminate between patients with and without re-stenosis.
These data suggested that, after vascular injury PTX3 may be
used as a marker of the inflammatory response and neointimal
thickening. Patients with re-stenosis after PCI presented a
positive transcardiac gradient, indicative of PTX3 production by
the coronary vasculature (93). The role of PTX3 in patients with
CAD was confirmed in a subsequent prospective observational
study on 75 ST elevation MI patients. High levels of PTX3
before PCI were associated with higher frequencies of plaque
rupture (49).
PTX3 levels were high in patients with small vessel vasculitis
and rheumatoid arthritis, but not in those with systemic lupus
erythematosus (94, 95). In small vessel vasculitis, a group of
autoimmune disorders characterized by inflammation of the
blood vessels, PTX3 plasma levels were higher in patients with
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active disease than in those with quiescent disease (95). EC are
responsible for PTX3 production, as shown by IHC performed
on skin sections at sites of vasculitis (96). Moreover, PTX3 is
more abundant at sites of leukocytoclastic infiltration (97). PTX3,
in contrast to the short pentraxin SAP, inhibits the uptake of
apoptotic PMNs by macrophages (97), suggesting that the long
pentraxin is a key factor in the incomplete clearance of apoptotic
and secondary necrotic PMNs observed in small-vessels vasculitis
(96). High circulating PTX3 levels were associated with vascular
injury in systemic lupus erythematosus patients, thus increasing
the dysfunction on the vascular endothelium (98).
PTX3 plasma levels also increase in patients with chronic
kidney disease (CKD) (99), and correlate with the severity of
the disease (100, 101). Hemodialysis (HD) patients have higher
circulating levels of PTX3 compared to peritoneal hemodialysis
patients (102). During the HD session, PTX3 plasma levels are
increased, suggesting that the protein could be a biomarker
of the HD-induced inflammation (103). In addition, in the
presence of peripheral or coronary artery disease, PTX3 levels
are significantly increased (102). Finally, high PTX3 levels predict
all-cause mortality and cardiovascular mortality in patients
with CKD (99), a finding reminiscent of MI data (56). PTX3
was associated with proteinuria and endothelial dysfunction
in patients with advanced CKD or type 2 diabetes (104),
suggesting that PTX3 is more than just an additional marker of
inflammation in chronic HF (105).
Preeclampsia, a pathological condition causing an exaggerated
inflammatory response resulting in endothelial dysfunction
(106–108), is a major complication of pregnancy. Circulating
levels of PTX3 are high in preeclampsia, underlining the strong
inflammatory response (108, 109). In addition, PTX3 levels in
the first trimester were altered in women who subsequently
developed preeclampsia, this confirming that an excessive
inflammatory response is one of the causal factors causing
preeclampsia in pregnant women (110).
CONCLUDING REMARKS
PTX3, the prototype member of the long pentraxin family,
is a soluble pattern recognition molecule with multifunctional
properties. Genetic approaches indicate that PTX3 is an
essential component of innate immunity and a modulator of
the inflammatory response. Not surprisingly in an intricate
field such as the immune/inflammatory response, PTX3 has
a dual character, one is good-protective against excessive
inflammatory response, the other is harmful- antiangiogenic
in cardiovascular diseases or inhibitor of phagocytosis in
nasopharyngeal carcinoma (111). In addition, the recent
observations on the involvement of PTX3 in tissue remodeling
and repair (23–26) may cast further light on the role of this
molecule in the cardiovascular pathology.
Current data are consistent with a role of PTX3 as a
novel marker of CVD (Figure 3). In general, PTX3 levels
rise rapidly, reflecting the inflammatory response affecting
vascular involvement. Thus, PTX3 has a different kinetics of
production and different patterns of recognized ligands from
CRP, a much more widely used biomarker of inflammation
and infection. Data available so far propose that CRP and
PTX3 could serve as complementary biomarkers of pathological
conditions, with CRP reflecting a systemic response while PTX3
is mainly produced locally. However, one must acknowledge
that, while the functional role of PTX3 in some vascular
disorders, i.e., atherosclerosis and MI, has been well-described,
in HF and CA, PTX3 has been explored only as a biomarker
and there is little evidence of its functional involvement.
In fact, the crucial question on each candidate biomarker
is “How long can a biomarker be called “emerging”? Are
10 years enough? Or better 20? How long should we
keep searching for evidence? It is impossible to answer
this rationallly. Although almost 50 years passed since the
discovery of natriuretic peptides and their functions, the
evidence of benefits obtained from their clinical monitoring is
still incomplete.
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